Vertex Inc. A

Vertex shares climbed to a record high, rising 1.7 percent on Wednesday to $558.36. Morgan Stanley reinstated coverage with an "overweight" rating and a $665 price target, the highest among Bloomberg‑tracked analysts. The price boost is supported by the completed $10 billion acquisition of Crinetics, which brings Palsonify (approved for acromegaly) and the development candidate Atumelnant into the portfolio. Analyst sentiment remains strong: 26 of 31 tracked firms recommend buy. » More on deraktionaer.de

Vertex shares dropped about 13% after disappointing cloud growth, although the overall quarter was slightly above consensus. Management cut its 2026 cloud-growth forecast from 25% to 18%, citing delayed cloud migrations. Several analysts then lowered their price targets (examples: DA Davidson 15→12 USD, Stephens 20→18 USD, Baird 19→17 USD). Vertex also reported three executive appointments, including a new chief product and technology officer. » More on de.investing.com

Vertex names Chatelle Lynch as Chief People Officer, Carlos Mercuriali as Senior Vice President and regional manager for Europe, and Bala Chandran as Chief Product and Technology Officer. The appointments are intended to bolster talent management, regional expansion in Europe, and technological innovation for the company’s SaaS- and AI-first strategy. Vertex emphasizes that the new leaders will support further global growth and the company’s adaptation to increasing e-invoicing and real-time compliance requirements. » More on finanzen.net